Picture of Regeneron Pharmaceuticals logo

REGN — Regeneron Pharmaceuticals Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapSuper Stock

Momentum

Relative Strength (%)
1m+6.06%
3m+17.79%
6m+20.56%
1yr+41.41%
Volume Change (%)
10d/3m-21.31%
Price vs... (%)
52w High-7.31%
50d MA+1.75%
200d MA+8.38%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)15.64
PEG Ratio (f)n/a
EPS Growth (f)-27.03%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.82
Price to Tang. Book3.82
Price to Free Cashflow9.59
Price to Sales4.61
EV to EBITDA7.64

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital38.96%
Return on Equity49.75%
Operating Margin55.08%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m5,872.236,710.87,863.48,497.116,071.711,776.7912,318.327.02%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+70.77+57.43-10.81+65.32+135.8-38.64+0.72n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for REGN

Stock market volatility: Here's a large-cap worth a closer look background image

Stock market volatility: Here's a large-cap worth a closer look

Shares in Regeneron Pharmaceuticals Inc (NSQ:REGN) are currently trading at 588.39 but the question for investors is how much the market chaos of 2020 will impact on its price. The answer comes down to judging whether Regeneron Pharmac...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Regeneron Pharmaceuticals EPS forecast chart

Profile Summary

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. Its product candidates in clinical development include REGN4018, REGN5668, and Fasinumab, among others.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
January 11th, 1988
Public Since
January 1st, 1991
No. of Shareholders
166
No. of Employees
10,368
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
109,846,194

REGN Share Price Performance

Latest News for REGN

Upcoming Events for REGN

Regeneron Pharmaceuticals Inc Annual Shareholders Meeting

Regeneron Pharmaceuticals Inc Annual Shareholders Meeting

Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference

Q2 2022 Regeneron Pharmaceuticals Inc Earnings Release

Q3 2022 Regeneron Pharmaceuticals Inc Earnings Release

Similar to REGN

Picture of 2Seventy Bio logo

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

Picture of AbSci logo

AbSci

us flag iconNASDAQ Global Select Market

Picture of Acadia Pharmaceuticals logo

Acadia Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email